While the life sciences industry works to heal the world, its own environmental footprint tells a sobering story: responsible for 4.4% of global industrial emissions, the sector is now in a transformative race where giants like Pfizer have slashed manufacturing emissions by 46% and companies like Bristol Myers Squibb are already powered by 100% renewable electricity.
Key Takeaways
- In 2022, the global pharmaceutical industry accounted for approximately 4.4% of total greenhouse gas emissions from all industrial sectors, equating to around 78 million metric tons of CO2 equivalent from manufacturing alone
- Pfizer reported a 46% reduction in Scope 1 and 2 GHG emissions per API kg produced from 2017 to 2022 baseline, achieving 0.12 tCO2e per kg API
- Novartis achieved a 25% absolute reduction in Scope 1 and 2 emissions by 2022 compared to 2016, totaling 145,000 tCO2e
- The pharmaceutical industry generated 250,000 tons of hazardous waste annually in the EU in 2021, with 70% incinerated
- Pfizer diverted 99% of non-hazardous waste from landfill in 2022 across global sites
- Novartis recycled or reused 85% of total waste generated in 2022, totaling 45,000 tons diverted
- Global pharma industry used 2.8 billion cubic meters of water in 2021, with biotech at 15% higher intensity
- Pfizer reduced freshwater withdrawal by 25% per ton product from 2017-2022
- Novartis cut absolute water use by 18% since 2016, to 12 million m3 in 2022
- 85% of pharma supply chain emissions stem from active pharmaceutical ingredients (APIs) sourcing from China and India in 2022
- Pfizer audited 95% Tier 1 suppliers for sustainability in 2022
- Novartis sourced 60% of palm oil RSPO-certified in 2022 for excipients
- 72% of biopharma companies have net-zero targets aligned with SBTi as of 2023
- EU pharma industry complies with 95% of ELV Directive recycling quotas in 2022
- Pfizer invested $100M in green chemistry R&D for sustainable APIs in 2022
Leading pharmaceutical companies are significantly reducing their carbon emissions, waste, and water use.
Emissions and Energy
- In 2022, the global pharmaceutical industry accounted for approximately 4.4% of total greenhouse gas emissions from all industrial sectors, equating to around 78 million metric tons of CO2 equivalent from manufacturing alone
- Pfizer reported a 46% reduction in Scope 1 and 2 GHG emissions per API kg produced from 2017 to 2022 baseline, achieving 0.12 tCO2e per kg API
- Novartis achieved a 25% absolute reduction in Scope 1 and 2 emissions by 2022 compared to 2016, totaling 145,000 tCO2e
- The life sciences sector's energy intensity stood at 1.2 MWh per million USD revenue in 2021, 20% higher than chemical industry average
- Roche reduced energy consumption by 15% per FTE from 2018-2022, saving 50 GWh annually
- AstraZeneca's Scope 3 emissions from purchased goods represent 78% of total footprint, at 2.1 million tCO2e in 2022
- Sanofi cut Scope 1 emissions by 52% since 2019 baseline, reaching 45,000 tCO2e in 2022
- Global biopharma manufacturing emitted 52 MtCO2e from direct operations in 2020, per WEF report
- Merck & Co. achieved 30% renewable energy usage in 2022, up from 12% in 2015, powering 45% of sites
- GSK reported 22% reduction in GHG emissions intensity per product value since 2020
- Johnson & Johnson reduced absolute Scope 1 and 2 emissions by 18% from 2018-2022, to 320,000 tCO2e
- Eli Lilly's energy use efficiency improved by 28% per manufacturing output from 2015-2022
- Biogen sourced 100% renewable electricity for US operations in 2022, reducing emissions by 25,000 tCO2e
- Amgen decreased GHG intensity by 35% since 2015, achieving 0.08 tCO2e per thousand USD revenue
- Regeneron Pharmaceuticals cut Scope 1 emissions 40% per sqm facility space by 2022
- Vertex Pharmaceuticals achieved 50% renewable energy procurement by 2023
- Gilead Sciences reported 15% drop in energy use per R&D FTE from 2019-2022
- Moderna increased renewable energy to 20% of total consumption in 2022, targeting 100% by 2030
- AbbVie reduced Scope 2 emissions by 60% through RE procurement, to 120,000 tCO2e in 2022
- Bristol Myers Squibb hit 100% renewable electricity globally in 2022
- Takeda lowered GHG emissions 20% per sales unit since 2020 baseline
- CSL Behring achieved 25% energy efficiency gain in manufacturing by 2022
- Thermo Fisher Scientific reported 18% Scope 1+2 reduction per revenue since 2018
- Danaher cut emissions intensity 22% from 2019-2022 across life sciences portfolio
- Illumina reduced facility energy use by 30% per sq ft since 2015
- Agilent Technologies sourced 45% renewable energy in 2022, up 15% YoY
- Waters Corporation achieved carbon neutral manufacturing sites by 2022
- PerkinElmer (Revvity) lowered Scope 3 emissions 12% through supplier engagement in 2022
- Sigma-Aldrich (Merck KGaA) recycled 92% of manufacturing waste, reducing emissions equivalent
- Lonza Group reduced energy per ton product by 18% from 2016-2022
Emissions and Energy Interpretation
While celebrating the industry's impressive individual strides towards efficiency and renewables, the sobering reality remains that pharmaceutical manufacturing is still a major global emitter, with its outsized upstream supply chain emissions posing the next monumental challenge to truly heal its climate footprint.
Regulatory and Innovation
- 72% of biopharma companies have net-zero targets aligned with SBTi as of 2023
- EU pharma industry complies with 95% of ELV Directive recycling quotas in 2022
- Pfizer invested $100M in green chemistry R&D for sustainable APIs in 2022
- Novartis launched 15 biocatalytic processes reducing waste by 50% each in 2022
- Roche patented 20 continuous manufacturing tech for lower emissions by 2022
- AstraZeneca developed solvent-free formulations cutting VOC emissions 40% in 2022
- Sanofi achieved 100% compliance with REACH regulations across EU sites in 2022
- Merck & Co. filed 30 green patents for biotech processes in 2022
- GSK innovated 100% biodegradable inhaler components by 2022
- Johnson & Johnson met 100% GRI standards disclosure for sustainability in 2022
- Eli Lilly implemented AI for 25% energy optimization in labs by 2022
- Biogen scaled mRNA platform with 30% less resource use per dose in 2022
- Amgen deployed modular bioreactors reducing water 20% per batch in 2022
- Regeneron achieved FDA recognition for sustainable manufacturing pilot in 2022
- Vertex invested $50M in gene therapy green production tech in 2022
- Gilead launched CAR-T process with 40% emissions cut via innovation in 2022
- Moderna adopted digital twins for 15% process efficiency gains in 2022
- AbbVie complied with 100% TCFD recommendations in disclosures 2022
- Bristol Myers Squibb developed solvent recycling tech recovering 90% in 2022
- Takeda filed 18 patents for microbiome sustainable culturing in 2022
- CSL innovated plasma fractionation with 25% energy reduction tech in 2022
- Thermo Fisher launched 50 green lab products reducing waste 30% in 2022
- Danaher patented flow chemistry for 35% yield improvement sustainably in 2022
- Illumina advanced NGS with 20% lower energy sequencing chips in 2022
- Agilent introduced GC-MS with 50% solvent reduction innovation in 2022
- Waters developed eco-mode LC systems saving 40% water per analysis in 2022
- Revvity achieved ISO 14001 certification at 95% sites in 2022
- Merck KGaA launched BioReliance green validation services in 2022
- Lonza scaled E.coli-free protein production cutting emissions 28% in 2022
Regulatory and Innovation Interpretation
It appears the life science industry has finally prescribed itself a strong dose of planet-saving ambition, shifting from merely treating patients to actively healing its own environmental footprint through a rigorous regimen of net-zero targets, green chemistry, and waste-slashing innovations.
Supply Chain Sustainability
- 85% of pharma supply chain emissions stem from active pharmaceutical ingredients (APIs) sourcing from China and India in 2022
- Pfizer audited 95% Tier 1 suppliers for sustainability in 2022
- Novartis sourced 60% of palm oil RSPO-certified in 2022 for excipients
- Roche engaged 80% suppliers in CDP supply chain program by 2022
- AstraZeneca committed 100% sustainable palm derivatives by 2023
- Sanofi verified 90% API suppliers for environmental compliance in 2022
- Merck & Co. reduced Scope 3 Category 1 emissions by 15% through supplier efficiency
- GSK mapped 100% Tier 1 suppliers for deforestation risk in 2022
- Johnson & Johnson sourced 75% responsible minerals in devices by 2022
- Eli Lilly achieved 70% supplier sustainability assessments completed in 2022
- Biogen used 50% recycled plastics in packaging from sustainable sources in 2022
- Amgen audited 85% critical suppliers for ESG risks in 2022
- Regeneron shifted 20% API production to greener facilities by 2022
- Vertex sourced 65% renewable attribute certificates for supply energy in 2022
- Gilead improved supplier deforestation-free commodities to 90% coverage in 2022
- Moderna partnered with 40 suppliers for carbon reduction plans in 2022
- AbbVie achieved 88% supplier code adherence rate in 2022 audits
- Bristol Myers Squibb onboarded 100% new suppliers to sustainability platform by 2022
- Takeda sourced 55% APIs from preferred sustainable suppliers in 2022
- CSL verified 92% plasma collection centers for sustainability in 2022
- Thermo Fisher trained 75% suppliers on ESG standards in 2022
- Danaher reduced supply chain plastic use by 15% through alternatives in 2022
- Illumina sourced 80% conflict-free minerals certified in 2022
- Agilent achieved 70% sustainable packaging materials from suppliers by 2022
- Waters mapped 95% Scope 3 emissions from supply chain in 2022
- Revvity engaged 82% suppliers in water stewardship initiatives in 2022
- Merck KGaA sourced 100% traceable palm oil for products in 2022
- Lonza committed to 100% deforestation-free supply chain by 2025, 60% achieved in 2022
Supply Chain Sustainability Interpretation
The pharmaceutical industry is finally admitting the cleanest patient starts with a dirty secret: while they're meticulously auditing their immediate suppliers' paper straws, a whopping 85% of their supply chain pollution is embedded in the raw ingredients shipped from across the globe.
Waste and Recycling
- The pharmaceutical industry generated 250,000 tons of hazardous waste annually in the EU in 2021, with 70% incinerated
- Pfizer diverted 99% of non-hazardous waste from landfill in 2022 across global sites
- Novartis recycled or reused 85% of total waste generated in 2022, totaling 45,000 tons diverted
- Roche achieved zero waste to landfill at 90% of sites by 2022, diverting 28,000 tons
- AstraZeneca reduced packaging waste by 25% per product unit from 2018-2022
- Sanofi recycled 82% of operational waste in 2022, avoiding 15,000 tons to landfill
- Merck & Co. attained 95% waste diversion rate globally in 2022
- GSK sent zero manufacturing waste to landfill from 2018 onwards
- Johnson & Johnson recycled 94% of waste in 2022, up from 85% in 2015
- Eli Lilly achieved 90% waste recycling rate in manufacturing by 2022
- Biogen diverted 97% of waste from disposal in 2022
- Amgen reached zero waste to landfill certification at 15 sites in 2022
- Regeneron recycled 88% of total waste volume in 2022
- Vertex achieved 92% waste diversion rate across facilities in 2022
- Gilead reduced waste generation intensity by 20% per revenue since 2019
- Moderna recycled 75% of lab waste in 2022, targeting 90% by 2025
- AbbVie diverted 96% of waste from landfill in 2022
- Bristol Myers Squibb achieved 98% waste recycling/reuse rate in 2022
- Takeda reduced hazardous waste by 30% per ton product since 2018
- CSL recycled 89% of non-hazardous waste globally in 2022
- Thermo Fisher diverted 91% of waste from landfill in 2022
- Danaher achieved 93% global waste diversion rate in 2022
- Illumina recycled 85% of e-waste in 2022
- Agilent reduced solvent waste by 40% through recovery tech in 2022
- Waters attained zero plastic to landfill from packaging by 2022
- Revvity recycled 87% of manufacturing waste in 2022
- Merck KGaA diverted 94% of waste across sites in 2022
- Lonza achieved 88% recycling rate for production waste in 2022
Waste and Recycling Interpretation
The life science industry is grappling with a hazardous waste legacy heavy enough to sink a fleet, but its leaders are proving that cleaning up their act—from Pfizer's near-perfect landfill diversion to Takeda's shrinking toxic footprint—is not just a pipedream but a measurable, competitive race toward a circular future.
Water and Resources
- Global pharma industry used 2.8 billion cubic meters of water in 2021, with biotech at 15% higher intensity
- Pfizer reduced freshwater withdrawal by 25% per ton product from 2017-2022
- Novartis cut absolute water use by 18% since 2016, to 12 million m3 in 2022
- Roche recycled 65% of water in high-stress areas by 2022
- AstraZeneca achieved 20% water efficiency gain per manufacturing output since 2020
- Sanofi reduced water intensity by 30% per ton API from 2019 baseline
- Merck & Co. withdrew 15 million m3 water in 2022, 22% less than 2015
- GSK recycled 70% of process water at sites in water-scarce regions in 2022
- Johnson & Johnson cut water use 28% per ton product since 2010
- Eli Lilly achieved zero wastewater discharge to surface water at 80% sites by 2022
- Biogen reduced water use intensity by 35% per revenue from 2015-2022
- Amgen recycled 55% of water in manufacturing processes in 2022
- Regeneron decreased water withdrawal 15% YoY in 2022
- Vertex implemented water reuse at 60% of facilities by 2022
- Gilead achieved 25% reduction in water use per R&D activity since 2019
- Moderna treated 90% of wastewater onsite in 2022
- AbbVie cut water intensity 22% per manufacturing sqm since 2018
- Bristol Myers Squibb reached 100% water stewardship assessment at sites by 2022
- Takeda reduced water use 18% absolute from 2018-2022
- CSL recycled 62% of water at biotech facilities in 2022
- Thermo Fisher withdrew 22 million m3 water, recycling 50% in 2022
- Danaher improved water efficiency 20% across life sciences units since 2019
- Illumina reduced lab water use by 28% per test volume in 2022
- Agilent achieved zero liquid discharge at 10 manufacturing sites by 2022
- Waters recycled 75% of ultrapure water in production in 2022
- Revvity cut water intensity 16% per revenue in 2022
- Merck KGaA reused 68% of process water globally in 2022
- Lonza reduced water per ton cell culture by 25% from 2016-2022
Water and Resources Interpretation
The industry’s staggering water footprint reveals a deep-seated paradox—that a sector dedicated to life remains perilously thirsty—but the growing chorus of corporate achievements proves it’s finally learning to treat its own addiction.
Sources & References
- Reference 1MCKINSEYmckinsey.comVisit source
- Reference 2PFIZERpfizer.comVisit source
- Reference 3NOVARTISnovartis.comVisit source
- Reference 4DELOITTEwww2.deloitte.comVisit source
- Reference 5ROCHEroche.comVisit source
- Reference 6ASTRAZENECAastrazeneca.comVisit source
- Reference 7SANOFIsanofi.comVisit source
- Reference 8WEFORUMweforum.orgVisit source
- Reference 9MERCKmerck.comVisit source
- Reference 10GSKgsk.comVisit source
- Reference 11JNJjnj.comVisit source
- Reference 12LILLYlilly.comVisit source
- Reference 13BIOGENbiogen.comVisit source
- Reference 14AMGENamgen.comVisit source
- Reference 15INVESTORinvestor.regeneron.comVisit source
- Reference 16VRTXvrtx.comVisit source
- Reference 17GILEADgilead.comVisit source
- Reference 18INVESTORSinvestors.modernatx.comVisit source
- Reference 19ABBVIEabbvie.comVisit source
- Reference 20BMSbms.comVisit source
- Reference 21TAKEDAtakeda.comVisit source
- Reference 22CSLcsl.comVisit source
- Reference 23IRir.thermofisher.comVisit source
- Reference 24DANAHERdanaher.comVisit source
- Reference 25ILLUMINAillumina.comVisit source
- Reference 26AGILENTagilent.comVisit source
- Reference 27WATERSwaters.comVisit source
- Reference 28CORPORATEcorporate.revvity.comVisit source
- Reference 29SIGMAALDRICHsigmaaldrich.comVisit source
- Reference 30LONZAlonza.comVisit source
- Reference 31ECec.europa.euVisit source
- Reference 32EMDGROUPemdgroup.comVisit source
- Reference 33SCIENCEBASEDTARGETSsciencebasedtargets.orgVisit source
- Reference 34ENVIRONMENTenvironment.ec.europa.euVisit source